Discovery, Structure-Activity Relationships, Pharmacokinetics, and Efficacy of Glucokinase Activator (2R)-3-Cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675)

被引:40
作者
Haynes, Nancy-Ellen [1 ]
Corbett, Wendy L. [1 ]
Bizzarro, Fred T. [1 ]
Guertin, Kevin R. [1 ]
Hilliard, Darryl W. [1 ]
Holland, George W. [1 ]
Kester, Robert F. [1 ]
Mahaney, Paige E. [1 ]
Qi, Lida [1 ]
Spence, Cheryl L. [2 ]
Tengi, John [1 ]
Dvorozniak, Mark T. [2 ]
Railkar, Aruna [3 ]
Matschinsky, Franz M. [4 ,5 ]
Grippo, Joseph F. [2 ]
Grimsby, Joseph [2 ]
Sarabu, Ramakanth [1 ]
机构
[1] Hoffmann La Roche Inc, Dept Discovery Chem, Nutley, NJ 07110 USA
[2] Hoffmann La Roche Inc, Dept Metab & Vasc Dis, Nutley, NJ 07110 USA
[3] Hoffmann La Roche Inc, Dept Non Clin Drug Safety & Discovery Technol, Nutley, NJ 07110 USA
[4] Univ Penn, Sch Med, Dept Biochem, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Ctr Diabet, Philadelphia, PA 19104 USA
关键词
AMIDES;
D O I
10.1021/jm100039a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Glucokinase (GK) is a glucose sensor that couples glucose metabolism to insulin release. The important role of GK in maintaining glucose homeostasis is illustrated in patients with GK mutations. In this publication, identification of the hit molecule 1 and its SA R development, which led to the discovery of potent allosteric GK activators 9a and 21a, is described. Compound 21a (RO0281675) was used to validate the clinical relevance of targeting GK to treat type 2 diabetes.
引用
收藏
页码:3618 / 3625
页数:8
相关论文
共 16 条
[1]   SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides:: Discovery of PSN-GK1 [J].
Bertram, Lisa S. ;
Black, Daniel ;
Briner, Paul H. ;
Chatfield, Rosemary ;
Cooke, Andrew ;
Fyfe, Matthew C. T. ;
Murray, P. John ;
Naud, Frederic ;
Nawano, Masao ;
Procter, Martin J. ;
Rakipovski, Guenaj ;
Rasamison, Chrystelle M. ;
Reynet, Christine ;
Schofield, Karen L. ;
Shah, Vilas K. ;
Spindler, Felix ;
Taylor, Amanda ;
Turton, Roy ;
Williams, Geoffrey M. ;
Wong-Kai-In, Philippe ;
Yasuda, Kosuke .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (14) :4340-4345
[2]   Glucokinase-activating ureas [J].
Castelhano, AL ;
Dong, HQ ;
Fyfe, MCT ;
Gardner, LS ;
Kamikozawa, Y ;
Kurabayashi, S ;
Nawano, M ;
Ohashi, R ;
Procter, MJ ;
Qiu, L ;
Rasamison, CM ;
Schofield, KL ;
Shah, VK ;
Ueta, K ;
Williams, GM ;
Witter, D ;
Yasuda, K .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) :1501-1504
[3]   Glucokinase activators in diabetes management [J].
Coghlan, Matthew ;
Leighton, Brendan .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (02) :145-167
[4]   From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].
DeFronzo, Ralph A. .
DIABETES, 2009, 58 (04) :773-795
[5]  
Dunten P, 2004, FRONT DIABETES, V16, P145
[6]   A novel glucokinase activator modulates pancreatic islet and hepatocyte function [J].
Efanov, AM ;
Barrett, DG ;
Brenner, MB ;
Briggs, SL ;
Delaunois, A ;
Durbin, JD ;
Giese, U ;
Guo, HH ;
Radloff, M ;
Gil, GS ;
Sewing, S ;
Wang, Y ;
Weichert, A ;
Zaliani, A ;
Gromada, J .
ENDOCRINOLOGY, 2005, 146 (09) :3696-3701
[7]   THE CONVERSION OF CARBOXYLIC-ACIDS INTO AMIDES VIA NCS TRIPHENYLPHOSPHINE [J].
FROYEN, P .
SYNTHETIC COMMUNICATIONS, 1995, 25 (07) :959-968
[8]  
Grimsby J, 2004, FRONT DIABETES, V16, P360
[9]   Glucokinase Activators for the Potential Treatment of Type 2 Diabetes [J].
Grimsby, J. ;
Berthel, S. J. ;
Sarabu, R. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (17) :1524-1532
[10]   Allosteric activators of glucokinase: Potential role in diabetes therapy [J].
Grimsby, J ;
Sarabu, R ;
Corbett, WL ;
Haynes, NE ;
Bizzarro, FT ;
Coffey, JW ;
Guertin, KR ;
Hilliard, DW ;
Kester, RF ;
Mahaney, PE ;
Marcus, L ;
Qi, LD ;
Spence, CL ;
Tengi, J ;
Magnuson, MA ;
Chu, CA ;
Dvorozniak, MT ;
Matschinsky, FM ;
Grippo, JF .
SCIENCE, 2003, 301 (5631) :370-373